Drug intelligence / Profile preview

Affinitac + cisplatin + gemcitabine

Development stage: Unknown
Lead developer: Ionis Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

This appears to be a combination therapy consisting of Affinitac (likely a selective high affinity ligand drug) with cisplatin and gemcitabine. Based on available information, Affinitac may be related to SH7139, a selective high affinity ligand (SHAL) oncology drug candidate designed to target and bind to HLA-DR proteins overexpressed by B-cell lymphomas. The combination with cisplatin (a platinum-based chemotherapy agent) and gemcitabine (a nucleoside analog) suggests this may be used for cancer treatment, potentially for non-Hodgkin's lymphoma or other solid tumors.

Targets

DNAPRKCA (Protein kinase C alpha)RNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on Affinitac + cisplatin + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Affinitac + cisplatin + gemcitabine.

Explore the full profile